79 results about "Drug metabolite" patented technology

The present invention provides a method of effectively measuring risk for therapeutic toxicity of a subject having an autoimmune disorder or cancer and predicting and evaluating therapeutic efficacy of immunosuppressive therapies for autoimmune diseases and cancers before or after starting therapy. The present invention also provides for determining a drug metabolite level of a subject during therapy and measuring periodically the drug metabolite level of a subject on maintenance therapy to ensure treatment compliance and continued therapeutic response by measuring minimal clinical important differences (MCID) in the drug metabolite levels. The present invention also provides for a method to effectively optimize the selection and dose of immunosuppressive therapies of a subject having an autoimmune disease or cancer to improve therapeutic efficacy and reduce therapeutic toxicity prior to starting concomitant biologic therapy and before or after the subject has failed to respond to the at least one immunosuppressive agent.

Isotopically-labeled species of propylene glycol and glycerol are provided as solvents for use in electronic nicotine delivery systems (e.g., as disposed in a cartridge in an e-cigarette). The isotopically-labeled species are distinguishable from the non-isotopically-labeled species (e.g., by mass spectrometry). Thus, methods are provided for the measurement of the quantity of solvent or of a solvent heating by-product (e.g., formaldehyde, acetaldehyde), or of a metabolite of the drug, delivered to a user by analysis of blood samples taken subsequent to dosing by use of the electronic nicotine delivery system. An example of an isotopically-labeled species of propylene glycol for use in such measurement methods is [¹³C]₃H₈O₂. A clinical study of e-cigarettes loaded with this isotopically-labeled species resulted in the following blood plasma concentration profiles in “vaping” subjects.

The invention provides for a novel dynamically configurable point-of-care device for clinical diagnostics and research for analysis of activity associated with pluripotent stem cells, tumor cells, drug metabolites, immunological response, glucose monitoring, cardiovascular diseases, liver cell therapy, cell-cell signaling, epidemic outbreaks, hospital based infectious diseases, pathogens, germ cells, pharmacological compounds, oxidation reduction, microscopy, tomography, flow cytometry, clinical lab testing, and for providing immunoassays, ELISA, electrophoresis, PCR, chromatography, and other laboratory functions. The device comprises a biochemical processing module further comprising a processor and at least one controller, receiving microfluidic elements, sensors, software scripts, an electrically operated interface, flow ports, a user interface, memory, and a communications link, configurable based on analysis of patient data. The invention further provides for multiple-criteria decision analysis for hospital administrators, a wearable device, mobile medical device, molecular electronics configuration, touchscreen recognition, data analytics application, and a drone delivery based point-of-care system.

The present invention is directed to a screening platform employing a miniaturized three-dimensional cell chip for high-throughput toxicology screening of test and lead compounds, prodrugs, drugs and P-450 generated drug metabolites. To this end, the three-dimensional cell chip, employs human cells encapsulated in a matrix (e.g., collagen or alginate gels) in volumes as small as 10 nL arrayed on a functionalized substrates (e.g., glass microscope slides) for spatially addressable screening against multiple test compounds. With the present platform, over 3,000 cell-matrix islands may be spotted providing for simultaneous screening against multiple compounds at multiple doses and in high replicate.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The application provides a detection method of nitrofuran drug metabolites in a meat product. The detection method comprises the following steps: (1) pretreatment comprising putting a sample into a pretreatment liquid, oscillating, then carrying out centrifugal separation, removing the clear liquid, and thus obtaining a solid residue; and (2) solid residue treatment comprising adding a derivatization agent into a sample solid residue extract liquid, carrying out derivatization treatment under conditions of heating, acidity and inert gas protection, after the derivatization treatment is completed, cooling, adjusting the pH to neutral, then centrifuging, taking the supernatant, then allowing the supernatant to pass through a solid-phase extraction column, leaching with a leaching liquid, carrying out elution treatment with an eluant to obtain an eluate, concentrating and drying the eluate, re-dissolving with a re-dissolving liquid, and thus obtaining a sample solution. The detection method can be applied to various animal-derived samples, and can shorten the hydrolyzed derivatization process to 30-60 minutes and shorten the whole detection process to 60-120 minutes.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The present invention discloses enzyme-linked immune kits for detecting nitrofurans metabolite residue including antigenic enzyme label plate coated with nitrofuran meatbolites, enzyme labeled antibody working fluid, standard solution, substrate solution, substrate buffer solution, reaction termination liquid, condense washing liquid and sample diluted concentrated liquid. The present invention also discloses using method for detecting by said kits including steps of pretreatment of sample, detecting with kits, result process and analysis and so on. The kits provided by present invention employ directly competing enzyme-linked immunoadsorption analysis to detect not only multiple nitrofurans metabolite residues at the same time, but also singleness nitrofurans metabolite residue, avoid many times detection of the same sample and reduce miss ratio, has merits of high sensitivity, good stability, less steps and low cost, and suit for screening of a large mount of samples, and has importance practical significance.

The invention discloses a preparation method of 3-methyl-2-ethanol based quinoxaline, comprising the following steps of: (1) in a solvent, carrying out reduction reaction on maquindox in the presence of a reducing agent to obtain 3-methyl-2-acetylquinoline; and (2) in the solvent, carrying out the reduction reaction on the 3-methyl-2-acetylquinoline in the presence of the reducing agent to obtain the 3-methyl-2-ethanol based quinoxaline. The 3-methyl-2-ethanol based quinoxaline of the invention is quinoxaline drug metabolites and can be used as a standard product for the residual and metabolism researches on quinoxaline drugs.

The invention provides a nitrofurans drug metabolite assay kit, which consists of a furazolidone metabolite test paper strip, a furaltadone metabolite test paper strip, a nitrofurazone metabolite test paper strip and a furantoin metabolite test paper strip. Each test paper strip consists of a sample pad, a colloidal gold pad, a nitrocellulose membrane, a sample adsorbing pad and a PVC (polyvinyl chloride) supporting plate, wherein the colloidal gold layer is a nitrofurans drug metabolite monoclonal antibody polyester film marked with colloidal gold, the nitrocellulose membrane is sequentially coated with nitrofurans drug metabolite coupled carrier protein as a test line (a T-line) and goat anti-mouse IgG antibody as a quality control line (a C-line). The nitrofurans drug metabolite assay kit is produced according to the nano colloidal gold technology, antigen-antibody specificity reactions and principles of immunity competitive inhibition reaction, and is used for testing whether samples contain nitrofurans drug metabolites or not.

The invention discloses a derivative of nitrofuran medicament metabolites as well as high performance liquid chromatography fluorescence detection. The method mainly comprises the following step that the derivative of the nitrofuran medicament metabolites is synthesized by matching sodium methylate, methyl alcohol and ethanol hydrazine according to certain dosage, and thus the liquid chromatography fluorescence detection is realized.

A process for chemically synthesizing albendazole-2-aminosulfone includes such steps as oxidizing reaction between albendazole, glacial acetic acid and H2O2 to obtain albendazole sulfone, reflux reaction in acid solution, regulating pH value to obtain coarse albendazole-2-aminosulfone, and recrystallizing.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The present invention relates to a monoclonal antibody and applications thereof, especially to a furazolidone metabolite derivative monoclonal antibody and applications thereof, and belongs to the technical field of immunochemistry. The furazolidone metabolite derivative monoclonal antibody 1C3' is produced by mouse hybridoma cell line 1C3, wherein a subtype is IgG1 type. According to the present invention, the monoclonal antibody 1C3' produced by the mouse hybridoma cell line 1C3 can be abundantly produced, and can be used to prepare an enzyme linked immunoassay kit and colloidal gold test paper strips for furazolidone metabolite (AOZ) detection so as to achieve a purpose of rapid and sensitive detection of furazolidone drug metabolites in muscle, liver and aquatic products and establish a foundation for furazolidone metabolite residue detection kit and colloidal gold product development.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Disclosed in certain embodiments is a method of analysis comprising quantifying the amount of a drug and/or drug metabolite in a keratinized sample of a subject that has been prescribed a dosing regimen of the drug to obtain a result; and comparing the result to a known standard value for the dosing regimen.

A system for the treatment of water to remove metals and noxious gases from well and groundwater so as to render the water potable is disclosed. The system employs microbubbles of oxygen, which remain suspended in water at a concentration above 100% of the calculated saturated concentration at a particular temperature and pressure. These microbubbles oxidize undesirable substances in the water, which substances include iron manganese, arsenic, antimony, chrome, aluminum, reduced sulfur compounds, pesticide residues, drug metabolites and/or bacteria. Microbubbles are produced by electrolysis or be sparging through a microorifice. A control system for the electrolytic system is disclosed.

The invention relates to the field of biomedicine, in particular to a construction method of a liver unit stent, a liver unit stent and application of the liver unit stent in the field of drug testing. The invention aims to provide a construction method of a liver unit stent, a liver unit stent and application of the liver unit stent in the field of drug testing. The construction method of the liver unit stent comprises the following steps: a gelled first composition, which includes hepatic parenchymatous cells and a biodegradable material, is loaded into a biological 3D printer, and an intermediate is printed according to a preset path; a cross-linking agent is dropwise added to the intermediate such that the biodegradable material in the intermediate is cross-linked to form a liver unitstent, wherein a channel is formed in the liver unit stent. In the liver unit stent, cell variety, quantity and position are controllable and the channel is controllable, thus providing a microenvironment for different cells. In addition, the liver unit stent can be used for researching the drug hepatotoxicity of new drugs and is used for detecting drug metabolites, gene expression, protein expression, cell apoptosis and cell proliferation.